Yusuf Khan, MD
Pulmonary Disease · Morrisville, PANPI 1962424655
Payments from drug & device makers
What this record shows
8 manufacturers reported payments, led by Jazz Pharmaceuticals Inc. at 38.0% of the total. Reporting peaked in 2019 at $371 and has fallen 81.5% since, to $69 in 2025. That places this record below the midpoint for pulmonary disease clinicians in PA, where the typical reported total is $988.
Across 29 payments — averaging $19.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Jazz Pharmaceuticals Inc.$219
- Sunovion Pharmaceuticals Inc.$136
- Harmony Biosciences LLC$55
- Insmed, Inc.$50
- Resmed Corp$35
- Electromed, Inc.$29
- plus $52 from 2 others
What the payments were for
- Food & beverage$25244%
- Education$32456%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Jazz Pharmaceuticals Inc. | 4 | $219 |
| Sunovion Pharmaceuticals Inc. | 16 | $136 |
| Harmony Biosciences LLC | 1 | $55 |
| Insmed, Inc. | 2 | $50 |
| Resmed Corp | 2 | $35 |
| Electromed, Inc. | 1 | $29 |
| Genentech USA, Inc. | 2 | $28 |
| Inspire Medical Systems, Inc. | 1 | $24 |
How this compares
$576 in reported general payments places this provider in the 40th percentile of 703 pulmonary disease providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 16 | $203,393 |
| XolairOmalizumab | 22 | $45,740 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 50 | $31,428 |
| Breo ElliptaFluticasone/Vilanterol | 55 | $30,315 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 37 | $29,311 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 15 | $12,579 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 23 | $11,396 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 47 | $10,381 |
| Roflumilast | 55 | $8,150 |
| Spiriva RespimatTiotropium Bromide | 12 | $8,076 |
| Incruse ElliptaUmeclidinium Bromide | 17 | $5,889 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 63 | $1,950 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 11 | $935 |
| Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide | 12 | $692 |
| Novolin RInsulin Regular, Human | 13 | $618 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Morrisville
- Sandeep Bansaldu Bois$1.4M
- Alan KanouffAltoona$809K
- Gerard CrinerPhiladelphia$657K
- Kenneth LanderUpland$647K
- Richard FriedenheimAbington$627K
- Thomas MeyerWynnewood$615K
- Surya BhattBethlehem$579K
- Tariq CheemaPittsburgh$549K
- Stephen KovacsErie$520K
- Michael ZlupkoAltoona$468K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.